Amgen Inc. $AMGN Position Raised by Schroder Investment Management Group

Schroder Investment Management Group raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 17.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 333,529 shares of the medical research company’s stock after purchasing an additional 48,384 shares during the quarter. Schroder Investment Management Group’s holdings in Amgen were worth $91,377,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. West Family Investments Inc. raised its stake in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after buying an additional 30 shares in the last quarter. Viawealth LLC boosted its stake in Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after buying an additional 30 shares in the last quarter. LOM Asset Management Ltd boosted its stake in Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after buying an additional 30 shares in the last quarter. TAGStone Capital Inc. grew its holdings in Amgen by 0.8% during the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock worth $1,157,000 after acquiring an additional 32 shares during the period. Finally, BBR Partners LLC raised its position in Amgen by 0.5% in the third quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after acquiring an additional 32 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on AMGN shares. Guggenheim upped their price target on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a report on Friday, February 6th. The Goldman Sachs Group lifted their price objective on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Daiwa Securities Group boosted their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. TD Cowen reissued a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, Scotiabank started coverage on shares of Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $354.17.

Amgen Stock Performance

AMGN stock opened at $376.97 on Tuesday. The firm has a 50 day moving average of $354.21 and a two-hundred day moving average of $323.38. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a market capitalization of $203.21 billion, a price-to-earnings ratio of 26.49, a P/E/G ratio of 3.67 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.